

Original Article

Ex-vivo expansion and function identification of CD4⁺ CD25⁺ CD127^{dim} regulatory T cells in severe aplastic anemia

Li Yan, Rong Fu, Huaquan Wang, Chunyan Liu, Hui Liu, Ting Wang, Weiwei Qi, Jing Guan, Zonghong Shao

Department of Hematology, General Hospital of Tianjin Medical University, Tianjin, China

Received February 19, 2016; Accepted July 12, 2016; Epub September 1, 2016; Published September 15, 2016

Abstract: Background: Regulatory T (Treg) cells play an important role in regulating immune responses. Successful ex-vivo expansion of Tregs has been achieved after T cell receptor (TCR) stimulation in the presence of T cell growth factors. In this study, we evaluated the proliferation ability and ex-vivo suppressive function of Tregs in severe aplastic anemia (SAA). Methods: To define the optimum population for Treg cell therapy in SAA, CD4⁺ CD25⁺ CD127^{dim} Treg subsets were sorted from the blood and bone marrow of SAA patients and normal controls, and expanded in vitro in the presence of anti-CD3/CD28 beads with high concentration of recombinant human interleukin 2 (rhIL-2). Their phenotype was determined by flow cytometry. Mixed lymphocytes culture with Teff was performed to assess the function of ex-vivo expanded Treg cells. Results: The Treg cells were expanded to approximately 10-fold in 1-2 weeks and retained the Treg cell phenotypic characteristics. Tregs from SAA patients even have more powerful proliferation ability than that from normal control. Moreover, the ex-vivo expanded Tregs have a high expression of CTLA-4. In ex-vivo immunosuppression experiment, the expansion rate of Teff from the four co-culture groups, including (control Teff: control Treg), (control Teff: SAA Treg), (SAA Teff: control Treg) and (SAA Teff: SAA Treg), did not show any significant difference. The IFN- γ secretion by Teff was suppressible by expanded Tregs from SAA patients. Conclusion: Tregs from SAA patient can be sorted and expanded successfully in vitro, and used efficiently to suppress effective T cells proliferation, paving the way for future clinical trials.

Keywords: Aplastic anemia, regulatory T cells, in vitro, expansion

Introduction

Acquired severe aplastic anemia (SAA) is a rare disease characterized by severe pancytopenia and bone marrow failure. Although the exact etiology is still unknown, previous studies have shown that it is an immune-mediated disease with destruction of hematopoietic cells by activated T cells [1, 2]. In recent years, many studies have demonstrated dysregulation of T cell function, especially that cytotoxic T lymphocytes (CTLs) leads to bone marrow failure in SAA [3, 4]. However, it remains unclear that how T cell become activated. Regulatory T cells (Tregs) is a special subset of T cells reported first by Sakaguchi in 1995 [5]. One of the major characteristics of Tregs is immunosuppression, which performed as inhibiting the activation and proliferation of CD4⁺ and CD8⁺ T cells, preventing the antigen presenting process of anti-

gen presenting cells (APC), and mediating target cell death directly. Studies have shown that Tregs played a pivotal role in controlling adaptive immune responses and maintenance of self-tolerance whether in mice or humans. Tregs express a variety of cell surface molecules, while some of them have a relatively close relationship with its function, such as CD25 (IL-2R α chain), FoxP3 (forkhead box protein 3), CTLA-4 (Cytotoxic T lymphocyte antigen, CD152), GITR (glucocorticoid-induced tumor necrosis factor receptor). Previous studies have shown that FoxP3 is required for Tregs to exert their suppressive ability and the ectopic expression of this transcription factor by lymphoid and non-lymphoid cells is able to confer suppressive function, making FoxP3 a critical regulator of Tregs function [6-8]. These FoxP3⁺ cells express high levels of CD25 and low levels of CD127 (FoxP3⁺ CD25^{high} CD127^{low} CD4⁺ T cells)

Ex-vivo expansion and function of tregs in SAA

[9]. CD127 expression is associated with acquisition of Tregs function [10]. It inversely correlates with FoxP3 expression and Tregs suppressive activity [11]. With the gradual understanding of Tregs, now more and more researchers use CD4⁺ CD25⁺ CD127^{dim} as the molecular markers of Tregs.

There is accumulating evidence that impaired function of Tregs has been implicated in the development of several common autoimmune diseases [12, 13], including SAA [14, 15]. Until now, most reports of Treg abnormality in aplastic anemia have shown that the numbers of circulating Tregs decreased in most patients. Tregs can be expanded from patient blood and were safely used in recent phase 1 studies in graft versus host disease (GVHD) [16, 17] and type 1 diabetes [18]. Treg cell therapy is also conceptually attractive for SAA. However, barriers exist to this approach. The stability of Tregs expanded from SAA patient is unknown. In this study, we intended to investigate the in vitro proliferation ability and function of expanded CD4⁺ CD25⁺ CD127^{dim} Tregs in SAA patients, and then provide a theoretical basis for cell targeted therapy of SAA.

Materials and methods

Study subjects

A total of thirty (seventeen males, thirteen females) patients with a median age of 25 years (range 7-65 years) were included in the study. This cohort of patients included eleven (three males, eight females) SAA cases who were previously untreated and nineteen cases (fourteen males, five females) with recovering-SAA (R-SAA).

The diagnosis of SAA was established by bone marrow biopsy, bone marrow smear, and peripheral blood cell count according to International AA Study Group Criteria [2]. SAA was defined by following criteria: (1) bone marrow cellularity <25% or 25-50% with <30% residual (hematopoietic) cells; (2) two of the following three: neutrophils <0.5 × 10⁹/L, platelets <20 × 10⁹/L, and reticulocytes <20 × 10⁹/L [19, 20]; (3) no evidence of malignant disease, no extensive iron deposition, storage disease, myelofibrosis, and no other autoimmune diseases. Bone marrow cytogenetic studies

were performed in all patients, and the clinical characteristics of patients are listed in **Table 1**.

Recovering SAA patients were defined as substantial improvement after therapy with rabbit antithymocyte globulin (rATG) (Fresenius, Germany), decreasing dose of cyclosporine (CsA), glucocorticoid and hematopoietic stimulating factors (recombinant human erythropoietin, granulocyte colony-stimulating factor, recombinant human thrombopoietin, and/or IL-11 in combination), and all the patients became completely transfusion independent. The duration of erythrocytes/platelets transfusion independence in 25%, 50% and 75% patients was 86/87, 140/126 and 196/183 days after ATG therapy, respectively. The median duration that neutrophils, erythrocytes and platelets returned to normal level was 35 days, 11 months and 12.5 months after ATG therapy, respectively. Among all the R-SAA patients, eleven have achieved complete response (CR), while the other eight were partial response (PR) according to Camitta criteria (1976).

Normal values of regulatory T cells counts were determined by fifteen age-matched healthy volunteers aged 18-71 years old. The study was approved by the Ethics Committee of the Tianjin Medical University. Informed written consent was obtained from all patients or their parents in accordance with the Declaration of Helsinki.

Flow cytometry

PB and BM mononuclear cells were stained with the following antibodies: CD4-PerCP, CD25-FITC, CD127-APC, CTLA-4-PE, and isotypic control mouse IgG₁-PE (all from BD Biosciences) according to the manufacturer's instructions. Data acquisitions were performed on a FACS-Calibur flow cytometer (BD Biosciences) and analyzed by FlowJo software (Version 7.6.1; TreeStar).

Purification of lymphocyte subpopulations

PB and BM mononuclear cells were separated by density-gradient centrifugation, respectively. Two T-cell subpopulations, including CD4⁺ CD25⁺ CD127^{dim} Tregs and CD4⁺ CD25⁻ effector T cells (Teff) were purified using a commercial human CD4⁺ CD25⁺ CD127^{dim} regulatory T cell isolation kit (Miltenyi Biotec) according to the manufacturer's instructions.

Ex-vivo expansion and function of tregs in SAA

Table 1. Clinical and demographic parameters of patients participating in the study

Diagnosis	Number	Age (years)	ANC ($\times 10^9/L$)	Hb (g/L)	PLT ($\times 10^9/L$)	Ret %	Bone marrow karyotype	Therapy	Duration (months)
Untreated SAA	11	16 (7-65)	0.62 \pm 0.82	64.38 \pm 13.68	15.05 \pm 13.33	0.39 \pm 0.30	Male 46, XY [20] Female 46, XX [20]	Not previously treated except for transfusions	2 (1-3)
Recovering SAA	19	26 (8-59)	2.95 \pm 1.87	126.21 \pm 33.58	128.96 \pm 62.93	2.45 \pm 1.85	Male 46, XY [20] Female 46, XX [20]	Treated with combination indicated	32 (6-116)

Values are expressed as mean \pm SD. Age and duration values are mid (min, max). ANC: Absolute neutrophil count; Hb: Hemoglobin; PLT: Platelet; Ret: Reticulocyte. Duration of "untreated SAA": from the onset of disease to time of Tregs measurement; duration of "recovering SAA": from the ATG therapy to time of Tregs measurement.

Ex-vivo expansion and function of tregs in SAA




Figure 1. A. The purity of sorted CD4⁺ CD25⁺ CD127^{dim} Treg. B. The purity of sorted CD4⁺ CD25⁻ Teff.

Treg proliferation

Once purified, Tregs were collected and cultured for 7-14 days at 37°C with 5% CO₂ in TexMACS™ Medium (Miltenyi Biotec) (100 µl/10⁵ cells) supplemented with 1% penicillin/streptomycin, 1% 2-mercaptoethanol, 1% non-essential amino acids (NEAA), 1% HEPES, 1% sodium pyruvate, 10% fetal calf serum (FBS), and 1000 U/mL rIL-2. MACSiBead Particles pre-loaded with CD3 and CD28 antibodies (Miltenyi Biotec) was added at a bead-to-cell ratio of 4:1. Tregs were cultured in a 96-well round-bottom plate (1 × 10⁵ cells/well). Change the culture medium, count the cells and save the supernatants one or two days. On day 7, the cells were re-stimulated with anti-CD3/CD28 beads.

Suppression assays

After cell proliferation, Tregs were mixed at a ratio of 1:4, and then added to autologous or allogeneic Teff cells seeded at 1 × 10⁵ cells/well in a 96-well round-bottom plate. To ensure accurate results, the experiment was repeated three times. Cells were cocultured for 2-3 days at 37°C with 5% CO₂ in TexMACS™ Medium (Miltenyi Biotec) (100 µl/10⁵ cells) supplemented with 1% penicillin/streptomycin, 1% 2-mercaptoethanol, 1% NEAA, 1% HEPES, 1% sodium

pyruvate and 10% FBS. MACSiBead Particles pre-loaded with CD3 and CD28 antibodies (Miltenyi Biotec) was added at 5 × 10⁴/well. CCK-8 reagent (Dojindo) was added at 10 µl/well (final concentration) during the last 4 hours of culture. Evaluation of cell proliferation was assayed by microplate reader and absorbance (A450 nm) was taken as the ability of cell proliferation. The cell proliferation rate was calculated using the formula: (absorbance of co-culture well/absorbance of blank well) × 100. For cross-culture experiments, Tregs from AA patients were mixed with autologous and healthy Teff at a ratio of 1:4, and vice versa.

Detection of levels of IL-10 and IFN-γ

Culture supernatants obtained from Tregs proliferation were analyzed for IL-10 by ELISA based on the manufacturer's instructions (USCNK). Supernatants obtained from the suppression assays were analyzed for IFN-γ based on the manufacturer's instructions (USCNK).

Statistical analysis

All analyses were performed using SPSS 21.0 software (SPSS Science). Data were presented as mean ± standard deviation (SD). The significance of the differences was assessed by One-way ANOVA. A value of *P* < 0.05 was considered statistically significant.

Ex-vivo expansion and function of tregs in SAA




Figure 2. A. At low magnification, Treg cells in culture at day 1. B. At low magnification, Treg cells in culture at day 8.




Figure 3. A. The growth curves of viable cell counts. B. The expansion rate of Treg cells from PB/BM of SAA (n=3/8), R-SAA (n=6/13) and normal control groups (n=7/7).

Results

Purity of CD4⁺ CD25⁺ CD127^{dim} Treg

CD4⁺ CD25⁺ CD127^{dim} Treg cells comprised approximately 5-10% of all the CD4⁺ T cells in the peripheral blood of human, while SAA patients had significantly decreased frequencies

of Tregs [21]. After sorting, the purity of CD4⁺ CD25⁺ CD127^{dim} Treg and CD4⁺ CD25⁻ Teff were both more than 80% (**Figure 1**).

Treg proliferation

Treg cells before and after culture is shown in **Figure 2**, and cell proliferation is obviously observed. **Figure 3A** shows the growth curves of viable cell counts at various time points, demonstrating approximately 10-fold expansion of the Treg cells. Tregs from SAA patients may have more powerful proliferation ability than that from normal control. The expansion rate of Treg cells from peripheral blood/bone marrow of SAA, R-SAA and normal control group were (17.54±10.34)/(9.21±8.54), (8.05±5.67)/(11.29±18.28) and (6.14±8.80)/(3.71±2.84), respectively (**Figure 3B**).

Cells were harvested according to their growth condition, and the purity was tested again by flow cytometry which still remain about 60% (**Figure 4A**). Based on the gate of CD4⁺ CD25⁺ CD127^{dim} Tregs and isotype control used by mouse anti-human IgG antibody, we analyzed the expression of the functional molecular marker CTLA-4 (**Figure 4B**). The result showed that the CTLA-4 expression of expanded Treg cells from SAA patients was more than 60%, substantially and significantly increasing when compared with Tregs before expansion [21].

IL-10, one of the most important cytokine secreted by Tregs, is a key inhibitor of effector T cell activation and a mediator of intestinal homeostasis [22]. The concentration of IL-10 in supernatants of cultured Tregs from

Ex-vivo expansion and function of tregs in SAA




Figure 4. A. The purity of ex-vivo expanded CD4⁺ CD25⁺ CD127^{dim} Tregs. B. The CTLA-4 expression of expanded Treg cells from SAA patients.




Figure 5. The concentration of IL-10 in supernatants of cultured Tregs from patients with SAA (n=12), R-SAA (n=10) and normal control (n=12).

SAA, R-SAA and normal control group were (27.82±35.92) pg/ml, (44.98±64.30) pg/ml and (50.94±65.91) pg/ml, without any significant difference (**Figure 5**).

Suppression assays

To address the efficiency of Treg-mediated immunosuppression for effector T cells, we carried out co-cultures of Treg/Teff and analyzed the cell proliferation of Teff at different condition, i.e. with or without autologous and allogeneic Tregs. **Figure 6** shows the growth curves of viable Teff cell counts at continuous time points of three days, demonstrating that Teff

from both normal control and SAA group cultured with Tregs from SAA patients showed at least equal to or even significantly worse proliferative abilities compared with those cultured with Tregs from normal control. Furthermore, the expansion rate of Teff in the cross-culture groups, including (control Teff: control Treg), (control Teff: SAA Treg), (SAA Teff: control Treg) and (SAA Teff: SAA Treg) were (1.89±0.49), (1.86±0.61), (1.94±0.64), and (1.90±0.64). The results did not show any significant difference within the four groups (**Figure 7**).

The concentration of IFN- γ in supernatants of the four cross-culture groups were (25.87±24.07) pg/ml, (21.89±18.65) pg/ml, (15.63±9.35) pg/ml, and (10.16±5.52) pg/ml, respectively (**Figure 8**). The control Teff: control Treg group was significantly higher than SAA Teff: SAA Treg, demonstrating that expanded Tregs from SAA patients may successfully suppress the IFN- γ secretion by Teff.

Discussion

As one of the key lymphocyte subpopulation to induce immune tolerance, Tregs are believed to control development and progression of autoimmunity by suppressing autoreactive T cells. Accumulating data provided evidence

Ex-vivo expansion and function of tregs in SAA




Figure 6. The growth curves of viable Teff cell counts at different condition. A. Teff cells from normal control. B. Teff cells from SAA patient.




Figure 7. The expansion rate of Teff in the four cross-culture groups, including (control Teff: control Treg) (n=10), (control Teff: SAA Treg) (n=7), (SAA Teff: control Treg) (n=87) and (SAA Teff: SAA Treg) (n=9).

that impaired function of Tregs contributed to the development of autoimmunity diseases, such as autoimmune hepatitis [23, 24], type 1 diabetes [25], multiple sclerosis [26], rheumatoid arthritis [27], and systemic lupus erythematosus. With the discovery that FoxP3 plays a central role in the differentiation and maintenance of Treg cells [6, 7], the use of flow cytometry-based analysis of FoxP3 expression in T cells became the gold standard for defining Treg cells. However, it then became evident that FoxP3 can also be expressed by effector T cells following activation [28], raising the possibility that any assessment of Treg cell number or function may include recently activated effector T cells in the Treg cell population. Furthermore, as FoxP3 is a nuclear protein, assessment of its expression in T cells requires fixation and permeabilization of the cells, resulting in an inability to obtain viable cells for further functional analysis. In the past few years, additional markers, such as CD127 (also known as IL-7R α) [11], have been identified that assist in the distinction of effector T cells from Treg cells and facilitate the experimental purification of Treg cells [29].




Figure 8. The concentration of IFN- γ in supernatants of the four cross-culture groups, including (control Teff: control Treg) (n=15), (control Teff: SAA Treg) (n=13), (SAA Teff: control Treg) (n=7) and (SAA Teff: SAA Treg) (n=8). *P<0.05.

An increasing number of studies have shown that SAA is an autoimmune disease caused by dysregulation of immune cell subsets, especially T lymphocytes [1, 30, 31]. There are several immune abnormalities associated with pathogenesis of SAA, including imbalance of DC subsets (elevated DC1), enhancement of DC function, insufficiency of regulatory T cell, imbalance of Th1/Th2 subsets (enhanced Th1), increase of type I lymphoid factors (IL-2, IFN- γ), and decrease of NK cell proportion [32]. Previous data have shown inadequate numbers of PB Tregs in patients with AA [14], and the quantities of Tregs in AA patients could be

Ex-vivo expansion and function of tregs in SAA

improved substantially after IST. Nevertheless, little is known regarding the function of Tregs in AA because of the attack of autologous T cells on BM hematopoietic progenitors. Recent studies have revealed several impairments of Tregs in AA. Kordasti and his colleagues have shown that sorted Tregs from AA patients were unable to suppress cytokine secretion (both IL-2 and IFN- γ) by autologous effector T cells [15]. Another study also reported the reversed ratio of Treg frequencies of BM versus PB, the abnormality of migratory potential, and defective immunosuppression on Teff cells in vitro [33].

Physiologically, Tregs probably have multiple suppressive mechanisms, and the importance of each one may vary depending on the environment and the context of immuneresponses [34]. Tregs have powerful ability to suppress proliferation of auto-reactive T cells through contact-dependent mechanisms or inhibitory cytokine production [13]. It is recognized that the fine immune homeostasis between Tregs and effector T cells, regulating immune homeostasis, is often disrupted in autoimmune disorders [12, 35-37], including aplastic anemia [38].

As has been shown in animal models and human studies, such low-Treg numbers in relation to effectors will not suppress immune responses [39]. Therefore, it is of particular importance to expand these cells *ex vivo* prior to administration to the patient, ensuring their stability and function is maintained in vitro. Fortunately, a few efficient strategies for the large-scale expansion of Tregs have been developed recently. Tregs are relatively refractory to T cell receptor (TCR) stimulation in vitro [40]; however, they can be driven to proliferate by combining TCR stimulation with high concentration of IL-2 [41] or IL-2 combined with IL-15 [42]. For example, large-scale *ex-vivo* expansion of human Tregs by stimulation with anti-CD3 and anti-CD28 monoclonal antibody-coated beads and high-dose IL-2 has successfully been demonstrated [43]. Importantly, these expanded cells retain their suppressor function both in vitro [44] and in vivo in animal models [45].

In this setting, we investigated the in vitro proliferation ability and function of expanded CD4⁺ CD25⁺ CD127^{dim} Tregs in SAA patients.

The results suggest that Treg cells from SAA patient can be sorted and expanded successfully with anti-CD3 and anti-CD28 monoclonal antibody-coated beads and high-dose IL-2 in vitro. Also it can be used efficiently to suppress effective T cells proliferation, paving the way for future clinical trials. Interestingly, the CTLA-4 expression of expanded Treg cells from SAA patients was substantially and significantly increasing when compared with Tregs before expansion. CTLA-4 is crucial for the suppressive function of Foxp3⁺ in vitro and in vivo [46]. It is expressed by Tregs which can modulate CD80 and CD86 expression by dendritic cells and there by inhibit the activation of effector T cells [47]. This provides us a hypothesis that there may be some kind of mechanism or abnormal microenvironment in SAA patient, which may somehow inhibit the function of Tregs in vivo. While once away from the morbid environment, Treg cells can be expanded and perform regular suppressive function in vitro. The further mechanism is under study and deserves to be investigated.

It has been hypothesized that an increased number of fully active Tregs could revert the imbalance of suppressor/effector cell ratio and may change the natural history of autoimmune diseases. Indeed, therapies that increase Treg numbers and activity have been shown to be effective at reversing autoimmune diseases in animal models such as experimental autoimmune encephalitis [48] and diabetes [49]. Of note, *ex vivo* expanded regulatory T cells, adoptively transferred in lupus-prone mice, reduced the rate of renal disease development, and a second transfer, in animals that already developed proteinuria, further delayed the progression of renal disease and significantly improved survival [50]. Moreover, a dose-escalation trial using autologous *ex vivo* expanded polyclonal Tregs (CD4⁺ CD25⁺ CD127^{dim/+}) in diabetes patients is currently ongoing [51].

We believe that in vitro expanded autologous/heterologous Tregs may help treating autoimmune diseases, including SAA, and that CD4⁺ CD25⁺ CD127^{dim} Treg cells are interesting from this point of view, because they appear to be a homeostatic attempt to counteract, at least in part, the disease. Nonetheless, like all therapies, clinical use of *ex-vivo*-expanded Treg cells is associated with potential risks. The most concerning is the possible instability of these

Ex-vivo expansion and function of tregs in SAA

ex-vivo-generated cells. There is at least a theoretical risk that these Tregs have the potential to revert to T effector cells in vivo, especially if antigen-specific Tregs are infused. In support of this, it has been shown that a minority of adoptively transferred Tregs loses FoxP3 expression and can differentiate into conventional T cells [52]. Understanding why and how Tregs lose their suppressive phenotype, the relevance of this in the clinical setting and in particular how this can be prevented would improve both the safety and efficacy of Treg cell therapy strategies.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (81400085, 81400088, 81570106, 81570111), Tianjin Municipal Natural Science Foundation (14JCYBJC25400, 15JCYBJC24300), Health Industry Research and Special Projects (201202017), Tianjin Cancer Research of Major Projects (12ZCDZSY17900, 12ZCDZSY18000), Tianjin Science and Technology support key project plan (20140109).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Zonghong Shao, Department of Hematology, General Hospital of Tianjin Medical University, 154 Anshandao, Heping District, Tianjin 300052, China. Tel: +86 226036-2086; Fax: +86 2260362085; E-mail: shaozonghong@sina.com

References

- [1] Young NS, Scheinberg P and Calado RT. Aplastic anemia. *Curr Opin Hematol* 2008; 15: 162-8.
- [2] Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, Keidan J, Laurie A, Martin A, Mercieca J, Killick SB, Stewart R, Yin JA. British Committee for Standards in, Guidelines for the diagnosis and management of aplastic anaemia. *Br J Haematol* 2009; 147: 43-70.
- [3] Fogarty PF, Yamaguchi H, Wiestner A, Baerlocher GM, Sloand E, Zeng WS, Read EJ, Lansdorp PM and Young NS. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. *Lancet* 2003; 362: 1628-30.
- [4] Maciejewski JP and Risitano A. Hematopoietic stem cells in aplastic anemia. *Arch Med Res* 2003; 34: 520-7.
- [5] Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol* 1995; 155: 1151-64.
- [6] Hori S, Nomura T and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science* 2003; 299: 1057-61.
- [7] Fontenot JD, Gavin MA and Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat Immunol* 2003; 4: 330-6.
- [8] Lipscomb MW, Taylor JL, Goldbach CJ, Watkins SC, Wesa AK and Storkus WJ. DC expressing transgene Foxp3 are regulatory APC. *Eur J Immunol* 2010; 40: 480-93.
- [9] Hartigan-O'Connor DJ, Poon C, Sinclair E and McCune JM. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. *J Immunol Methods* 2007; 319: 41-52.
- [10] Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, and Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. *J Exp Med* 2006; 203: 1693-700.
- [11] Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF and Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. *J Exp Med* 2006; 203: 1701-11.
- [12] Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. *Nat Rev Immunol* 2010; 10: 849-59.
- [13] Campbell DJ and Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. *Nat Rev Immunol* 2011; 11: 119-30.
- [14] Solomou EE, Rezvani K, Mielke S, Malide D, Keyvanfar K, Visconte V, Kajigaya S, Barrett AJ and Young NS. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. *Blood* 2007; 110: 1603-6.
- [15] Kordasti S, Marsh J, Al-Khan S, Jiang J, Smith A, Mohamedali A, Abellan PP, Veen C, Costantini B, Kulasekararaj AG, Benson-Quarm N, Seidl T, Mian SA, Farzaneh F and Mufti GJ.

Ex-vivo expansion and function of tregs in SAA

- Functional characterization of CD4+ T cells in aplastic anemia. *Blood* 2012; 119: 2033-43.
- [16] Yang J, Fan H, Hao J, Ren Y, Chen L, Li G, Xie R, Yang Y, Qian K and Liu M. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model. *Transfusion* 2012; 52: 1333-47.
- [17] Trzonkowski P, Bieniaszewska M, Juscinska J, Dobyszek A, Krzystyniak A, Marek N, Mysliwska J and Hellmann A. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. *Clin Immunol* 2009; 133: 22-6.
- [18] Yi S, Ji M, Wu J, Ma X, Phillips P, Hawthorne WJ and O'Connell PJ. Adoptive transfer with in vitro expanded human regulatory T cells protects against porcine islet xenograft rejection via interleukin-10 in humanized mice. *Diabetes* 2012; 61: 1180-91.
- [19] Camitta BM, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP, Rapoport JM and Storb R. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. *Blood* 1976; 48: 63-70.
- [20] Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT, Congiu M, De Planque MM, Ernst P, McCann S, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. *Br J Haematol* 1988; 70: 177-82.
- [21] Yan L, Fu R, Liu H, Wang H, Liu C, Wang T, Qi W, Guan J, Li L and Shao Z. Abnormal quantity and function of regulatory T cells in peripheral blood of patients with severe aplastic anemia. *Cell Immunol* 2015; 296: 95-105.
- [22] Seiffart V, Zoeller J, Klopffleisch R, Wadwa M, Hansen W, Buer J, Riedel C and Westendorf AM. IL10-Deficiency in CD4 T Cells Exacerbates the IFN γ and IL17 Response During Bacteria Induced Colitis. *Cell Physiol Biochem* 2015; 36: 1259-1273.
- [23] Longhi MS, Hussain MJ, Mitry RR, Arora SK, Mieli-Vergani G, Vergani D and Ma Y. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. *J Immunol* 2006; 176: 4484-91.
- [24] Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G and Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. *J Hepatol* 2004; 41: 31-7.
- [25] Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, Zhang ZY, Pihoker C, Sanda S, Greenbaum C and Buckner JH. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. *Diabetes* 2010; 59: 407-15.
- [26] Viglietta V, Baecher-Allan C, Weiner HL and Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. *J Exp Med* 2004; 199: 971-9.
- [27] Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA and Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF- α therapy. *J Exp Med* 2004; 200: 277-85.
- [28] Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH and Ziegler SF. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. *J Clin Invest* 2003; 112: 1437-43.
- [29] Sakaguchi S, Miyara M, Costantino CM and Hafler DA. FOXP3+ regulatory T cells in the human immune system. *Nat Rev Immunol* 2010; 10: 490-500.
- [30] Young NS. Autoimmunity and its treatment in aplastic anemia. *Ann Intern Med* 1997; 126: 166-8.
- [31] Nakao S. Immune mechanism of aplastic anemia. *Int J Hematol* 1997; 66: 127-34.
- [32] Zonghong S, Meifeng T, Huaquan W, Limin X, Jun W, Rong F, Hong L and Yuhong W. Circulating myeloid dendritic cells are increased in individuals with severe aplastic anemia. *Int J Hematol* 2011; 93: 156-62.
- [33] Shi J, Ge M, Lu S, Li X, Shao Y, Huang J, Huang Z, Zhang J, Nie N and Zheng Y. Intrinsic impairment of CD4(+)CD25(+) regulatory T cells in acquired aplastic anemia. *Blood* 2012; 120: 1624-32.
- [34] Sakaguchi S, Yamaguchi T, Nomura T and Ono M. Regulatory T cells and immune tolerance. *Cell* 2008; 133: 775-87.
- [35] Scheinecker C, Bonelli M and Smolen JS. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. *J Autoimmun* 2010; 35: 269-75.
- [36] Alunno A, Bartoloni E, Bistoni O, Nocentini G, Ronchetti S, Caterbi S, Valentini V, Riccardi C and Gerli R. Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. *Clin Dev Immunol* 2012; 2012: 823085.
- [37] Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, Wan L and Li M. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. *Arthritis Rheum* 2009; 60: 1472-83.
- [38] de Latour RP, Visconte V, Takaku T, Wu C, Erie AJ, Sarcon AK, Desierto MJ, Scheinberg P, Keyvanfar K, Nunez O, Chen J and Young NS.

Ex-vivo expansion and function of tregs in SAA

- Th17 immune responses contribute to the pathophysiology of aplastic anemia. *Blood* 2010; 116: 4175-84.
- [39] Safinia N, Sagoo P, Lechler R and Lombardi G. Adoptive regulatory T cell therapy: challenges in clinical transplantation. *Curr Opin Organ Transplant* 2010; 15: 427-34.
- [40] Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. *Cell* 2000; 101: 455-8.
- [41] Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R and Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25 high regulatory T cells. *Blood* 2004; 104: 895-903.
- [42] Karakhanova S, Munder M, Schneider M, Bonyhadi M, Ho AD and Goerner M. Highly efficient expansion of human CD4+CD25+ regulatory T cells for cellular immunotherapy in patients with graft-versus-host disease. *J Immunother* 2006; 29: 336-49.
- [43] Godfrey WR, Ge YG, Spoden DJ, Levine BL, June CH, Blazar BR and Porter SB. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. *Blood* 2004; 104: 453-61.
- [44] Levings MK, Sangregorio R and Roncarolo MG. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. *J Exp Med* 2001; 193: 1295-302.
- [45] Hoffmann P, Ermann J, Edinger M, Fathman CG and Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. *J Exp Med* 2002; 196: 389-99.
- [46] Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T and Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. *Science* 2008; 322: 271-5.
- [47] Walker LS and Sansom DM. Confusing signals: Recent progress in CTLA-4 biology. *Trends Immunol* 2015; 36: 63-70.
- [48] Davidson TS and Shevach EM. Polyclonal Treg cells modulate T effector cell trafficking. *Eur J Immunol* 2011; 41: 2862-70.
- [49] Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, and Bluestone JA. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. *J Exp Med* 2004; 199: 1455-65.
- [50] Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML and Daikh DI. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. *J Immunol* 2006; 177: 1451-9.
- [51] Thompson JA, Perry D and Brusko TM. Autoalogous regulatory T cells for the treatment of type 1 diabetes. *Curr Diab Rep* 2012; 12: 623-32.
- [52] Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H and Hori S. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. *Proc Natl Acad Sci U S A* 2009; 106: 1903-8.